Nordhealth AS – End of stabilization and partial exercise of greenshoe option
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Reference is made to the stock exchange announcement by Nordhealth AS (“Nordhealth” or the “Company”) on 3 June 2021 where the Company announced the beginning of the stabilization period following the private placement of new shares in the Company (the “Private Placement”) and the subsequent admission to trading on Euronext Growth Oslo.
Carnegie AS (“Carnegie”), acting as stabilization manager in connection with the Private Placement, hereby gives notice that stabilization was undertaken in relation to the shares in Nordhealth with a total of 2,081,990 shares purchased as part of the stabilization. The shares were purchased at an average price of NOK 39.8944 and stabilization last occurred on 9 June 2021.
Carnegie will redeliver the shares purchased through stabilization transactions to the selling shareholders in the Private Placement (the “Selling Shareholders”) in accordance with the terms in a share lending agreement between the parties. Carnegie has furthermore exercised the option to purchase at the offer price of NOK 40.786 per share 1,668,010 shares in Nordhealth from the Selling Shareholders, which were over-alloted in the Private Placement and for which the redelivery obligation under the share lending agreement has not been satisfied by delivery of the shares purchased during the stabilization period.
Carnegie AS acted as sole bookrunner (the “Manager”) in respect to the Private Placement. Advokatfirmaet Thommessen AS acted as legal counsel to the Company and Advokatfirmaet Haavind AS acted as legal counsel to the Manager.
For further information, please contact:
Carnegie AS
Stefan Schander Slemdal
Tel: +47 22 00 94 26
This information is subject of the disclosure requirements pursuant to Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 section 6 (3).
About Nordhealth
Nordhealth is a cloud-based healthcare SaaS company whose mission is to redefine digital healthcare. The Company’s products empower healthcare professionals to improve patient care, increase efficiency and expand their business. Since 2005, the Company has acquired and built cloud-based software for veterinary and therapeutic professionals and their patients, and now serves more than 30,000 professionals across 7,000 clinics and hospitals located in over 25 countries.
Headquartered in Espoo, Finland, Nordhealth has a solid footprint in the Nordic region and a growing presence internationally, with more than 240 employees working either remotely or from offices (collaboration hubs), serving a global customer base. Visit the company’s website at nordhealth.com.
